The Comparison of TP and NP regimen in the treatment of advanced non-small cell lung cancer

Objective:To assess the efficacy and toxicity of taxotere/cisplatin (TP) and vinorelbine/cisplatin in patients with advanced non-small cell lung cancer (NSCLC). Methods: Thirty-five patients were treated with TP regimen (taxotere +cisplatin), 39 patients were treated with NP regimen ( vinorelbine + cisplatin). Cycles were repeated every 3 weeks. Results:The overall response rate (RR) were 42.9% and 43.6% for the patients treated with TP and NP regimen respectively (χ2=0.09 ,P=0.763), the median survival time were 9.6 and 8.9 months for the patients treated with TP and NP regimen respectively ( P0.05), one year survival rate were 34.3% and 30.8% for the patients treated with TP and NP regimen respectively ( P0.05). Myelosuppression and gastrointestinal toxicities were major toxicity, there were no significant difference between two groups ( P0.05) . Phlebitis occurred in 5.7% and 23.1% in the patients treated with TP and NP regimen respectively (χ2=4.39, P=0.036), but no grade Ⅲ～Ⅳ phlebitis occurred. Concluslon: TP and NP regimens in patients with non-small cell lung cancer who have good performance status can moderately improve survival at one year. It deserves further clinical application.